ABSTRACT
Tc-99m MIBI has recently been used in the functional imaging of various tumors. This prospective study was performed to evaluate the role of Tc-99m MIBI imaging at the time of the initial staging, assessment of treatment response, follow-up studies and survaillance in Hodgkin's and non-Hodgkin's Iymphoma. 25 patients [14 with Hodgkin's and 11 with non-Hodgkin's Iymphoma] underwent 32 studies. The patient's age range wa 19-73 years, with a mean age of 41.7 years. All patients underwent whole body planar imaging following intravenous injection of 20-25 mCi Tc-99m MIBI. Comparative imaging with 3 mCi Tl-201 and 10 mCi Ga-67 injection was done. Clinical, radiographic and biopsy correlation was obtained in all cases
Subject(s)
Humans , Lymphoma, Non-Hodgkin/diagnostic imaging , Hodgkin Disease/diagnostic imaging , Technetium Tc 99m Sestamibi , Prospective Studies , Thallium Radioisotopes , Gallium RadioisotopesABSTRACT
The primary treatment of thyroid carcinoma is surgery and the outcome depends on its extent. The post-operative management alternatives in thyroid carcinoma include thyroid hormone, radio-iodine ablation [I-131 Na], external beam radiation therapy [EBRT] and occasionally adjuvant chemotherapy. This retrospective study analyzes the managements of 153 patients [102, 51], age range 10-96 years, mean age 50.2 years treated for thyroid carcinoma. The range of follow-up was 1.0-294 months with median follow-up for 60.4 months. Twenty patients without therapy were excluded. Group A included 87 patients treated with I-131. Group B consisted of 13 patients received EBRT. Group C included both therapies in 33 patients. The therapies in all different stages of thyroid carcinoma and with various histopathologies were reviewed